 NESS ZIONA, Israel, April 27, 2021 GLOBE NEWSWIRE -- Sol-Gel Technologies, Ltd. NASDAQ: SLGL, a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced an update regarding the U.S. Food and Drug Administration FDA approval process for EPSOLAY benzoyl peroxide 5 topical cream for the treatment of Inflammatory lesions of rosacea in adults. 